(Press-News.org) At the NRG Oncology Summer Meeting on Thursday, July 20, 2023, at approximately 5:44pm EDT, Larry J. Copeland, MD passed the presidential gavel to Thomas J. Herzog, MD at The GOG Foundation, Inc. (GOG-F) Board of Directors meeting.
Dr. Herzog brings a comprehensive background in clinical trials, the integral business aspects and acumen to this important position. A practicing gynecologic oncologist and member of the Board of Directors of GOG-F, he has served as the Treasurer of GOG-F from 2014-2023 and prior to taking presidential office, served as Associate Director of the GOG Partners (GOG-P) program. He is currently Deputy Director of the University of Cincinnati Cancer Center and Paul & Carolyn Flory Professor in the department of Obstetrics and Gynecology at the University of Cincinnati. Dr. Herzog has authored/co-authored over 325 peer-reviewed articles and lectures extensively nationally and internationally. He serves and has served on the editorial boards of Gynecologic Oncology, Obstetrics and Gynecology International, Hematology Oncology Times, and others. He served as Editor–In-Chief of Women’s Oncology Review and Gynecologic Oncology Research to Practice. Dr. Herzog has also served on the board of directors or leadership council of the Society of Gynecologic Oncology, the Foundation for Women’s Cancer, Board of Governors for the American College of Surgeons, American Board of Obstetrics and Gynecology-Gynecologic Oncology Division, and the International Gynecologic Cancer Society.
Dr. Herzog will be responsible for GOG-F, which includes the GOG Foundation corporate membership in the NRG Oncology Foundation, Inc., and GOG-P program. The GOG-F, formerly known as the Gynecologic Oncology Group, in collaboration with the NSABP Foundation, Inc. and the RTOG Foundation, Inc., formed a new 501(C)(3), in 2012, NRG Oncology Foundation, Inc. (NRG). In addition to the NRG responsibilities, Dr. Herzog will also oversee the GOG Partners program founded in 2013 and work alongside Dr. Robert Mannel, Senior Vice President of GOG-F. Dr. Mannel is also one of the Group Chairs that is responsible for the research conducted by the NRG Oncology clinical cooperative group that is a member of the NCI National Clinical Trials Network.
Dr. Herzog shares, “It is truly an amazing honor to be the next President of The GOG Foundation. I am cognizant of the need to ever improve our organization to face the challenges of maintaining our role as the premier clinical trials network in gynecologic malignancies in North America and beyond. Initiatives in diversity, operational transparency, translational research, site expansion, and improved trial efficiencies are ongoing, and will be further developed moving forward. In addition, I look forward to training our next generation of outstanding clinical trialists. Following a true legend like Dr. Copeland is not easy, but I pledge to honor the principles that he and Dr. DiSaia so effectively instilled in our group as tremendous leaders in our field. I look forward to Dr. Copeland’s continued involvement, wisdom, and guidance through his role as Immediate Past President. I have incredible confidence and trust in the ability of the amazing GOG-F physician leadership and staff teams to effectively navigate our path forward in transforming the standard of care for our patients afflicted with gynecologic malignancies.”
Larry J. Copeland, MD who now serves as Immediate Past President, has proven his success by the unprecedented growth in its clinical trials program, particularly in GOG-Partners (GOG-P), including a greatly expanded clinical trials portfolio, further expansion and engagement of its investigator base, development of a clinical trial mentorship program, and multiple educational initiatives focused on novel agents, clinical trial design and clinical trial execution. Dr. Copeland noted, “It has been an honor to serve the GOG Foundation over the past three decades, the last 6 years as the President. The many accomplishments over recent years must be attributed to the great team – both staff and physician leaders, who work tirelessly on a daily basis. Dr. Herzog is the perfect individual to oversee the continuation of the pursuit of the GOG Foundation mission to “Transform the Standard of Care”. I pledge him my full support in his future leadership role.” Dr. Copeland will continue to be involved in the day-to-day activity as Immediate Past President of the organization.
About The GOG Foundation, Inc. (www.gog.org)
The GOG Foundation, Inc. is a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and translational scientific research in the field of gynecologic malignancies. The GOG Foundation is committed to maintaining the highest standards in clinical trials development, execution, analysis, and distribution of results. The GOG Foundation is the only clinical trialist group in the United States that focuses its research on patients with pelvic malignancies, such as cancer of the ovary (including surface peritoneal malignancies), uterus (including endometrium, soft tissue sarcoma, and gestational trophoblastic neoplasia), cervix, and vulva. The GOG Foundation is multi-disciplinary in its approach to clinical trials, and includes gynecologic oncologists, medical oncologists, pathologists, radiation oncologists, oncology nurses, biostatisticians (including those with expertise in bioinformatics), basic scientists, quality of life experts, data managers, and administrative personnel.
About NRG Oncology (www.nrgoncology.org)
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and legacy Gynecologic Oncology Group, now The GOG Foundation, Inc. (GOG) programs. The research network seeks to conduct clinical trials with emphasis on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.
About GOG Partners Program
Supported by industry, GOG Partners is structured to work directly with pharmaceutical organizations and operate clinical trials outside the National Cancer Institute (NCI) framework. The GOG Partners Program shares the same mission of the GOG Foundation dedicated to transforming the care in Gynecologic Oncology. By providing an alternative venue for patient accrual and site infrastructure support, GOG Partners has helped provide additional trials and opportunities for patients outside the national gynecologic clinical trials network.
###
Corporate & Media Contact:
GOG Partners
Jenna Cummins, CMP, Executive Director of Business Development
773-750-5753, jcummins@gog.org
END
Thomas J. Herzog, MD takes office as The GOG Foundation, Inc. President
2023-07-31
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
ACP issues updated guidance for colorectal cancer screening of asymptomatic adults
2023-07-31
Embargoed for release until 5:00 p.m. ET on Monday 31 July 2023
Annals of Internal Medicine Tip Sheet
@Annalsofim
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf ...
Why you shouldn’t declaw tigers or other big cats
2023-07-31
Declawing house cats to keep them from scratching people and furniture is controversial – and even banned in some countries and areas in the U.S. – but the practice is not limited to house cats. In a new study, researchers looked at the effects of declawing on larger cat species and found that declawing disproportionately impacts their muscular capabilities as compared to their smaller brethren.
While it is illegal in the U.S. to surgically modify an exotic animal, declawing is still done on large cats like lions and tigers, often in an effort to allow cubs to more safely ...
Cutting-edge cancer research lab opens operations at Pepper Place
2023-07-31
BIRMINGHAM, Ala. – Birmingham’s Pepper Place has a striking new addition to its teeming farmers’ market and noted food offerings — a multimillion-dollar cancer research laboratory.
The lab is IN8bio’s new research and development facility in the Martin Biscuit Building at Pepper Place. This R&D space has about 6,000 square feet of wet lab space and around 4,000 square feet for offices, conferences and break areas. IN8bio is a biotechnology company focused on developing novel cellular therapies for cancer, with deep roots in cutting-edge cancer research developed at ...
New UArizona study links brain waves directly to memory
2023-07-31
Neurons produce rhythmic patterns of electrical activity in the brain. One of the unsettled questions in the field of neuroscience is what primarily drives these rhythmic signals, called oscillations. University of Arizona researchers have found that simply remembering events can trigger them, even more so than when people are experiencing the actual event.
The researchers, whose findings are published in the journal Neuron, specifically focused on what are known as theta oscillations, which emerge in the brain's hippocampus region during activities like exploration, navigation and sleep. The hippocampus plays ...
New chemical process makes it easier to craft amino acids that don’t exist in nature
2023-07-31
Every protein in your body is made up of the same 20 building blocks called amino acids. But just because nature is stuck with a limited toolkit doesn’t mean humans can’t expand it.
A study published in Science on July 27 by a team including Pitt chemists describes a powerful new way to create “unnatural” amino acids, which could find use in protein-based therapies and open up novel branches of organic chemistry.
“This is a completely new transformation: new to nature and new to chemistry,” ...
Social media marketing most effective when it prompts consumers to start posting
2023-07-31
Social media is a critical marketing tool to help raise awareness when firms launch new products. The platforms can help inform consumers about product characteristics and benefits relative to competitors’ products.
New research from the University of Notre Dame analyzes data from the motion picture industry, which often relies on social media promotion, in an effort to understand how marketers could better promote other new products.
“The Ripple Effect of Firm-Generated Content on New Movie Releases,” forthcoming in the Journal of Marketing Research ...
Study shows new stroke surgery eligibility criteria may dramatically increase lifesaving stroke surgery rates, with nationwide implications
2023-07-31
Study Shows New Stroke Surgery Eligibility Criteria May Dramatically Increase Lifesaving Stroke Surgery Rates, with Nationwide Implications
SAN DIEGO—A recent study presented today at the Society of NeuroInterventional Surgery’s (SNIS) 20th Annual Meeting noted that U.S. rates of endovascular thrombectomy, a lifesaving stroke treatment, are projected to increase dramatically based on new criteria.
In the study, endovascular thrombectomy was shown to improve clinical outcomes in patients with large ischemic strokes. This change has the ...
Lignin separation method could make renewable material profitable
2023-07-31
RICHLAND, Wash. – A novel method to extract lignin could help spin wheat straw into gold. Lignin produced using the new method was color-neutral, odorless and homogenous, an advance that could make this carbon-neutral material a more viable candidate for development of high-value products.
Reporting in the Proceedings of the National Academy of Sciences, the Washington State University researchers extracted up to 93% lignin with up to 98% purity from wheat straw, producing a significant amount of material in a uniform way that could make ...
Hydrogen sulfide shows promise as healthy ageing therapeutic when specifically targeted within cells
2023-07-31
Future therapies to help people live healthy lives for longer could be developed from drugs that release tiny amounts of the gas hydrogen sulfide (H2S), new research has indicated.
A study from the University of Exeter, funded by the US Army and charity The United Mitochondrial Disease Foundation, found that targeting tiny amounts of H2S to specific areas of cells in adult worms using a H2S-releasing molecule called AP39, greatly improved health and activity as they aged. The research, published in PNAS, concludes that targeting ...
MIT engineers create an energy-storing supercapacitor from ancient materials
2023-07-31
CAMBRIDGE, Mass. -- Two of humanity's most ubiquitous historical materials, cement and carbon black (which resembles very fine charcoal), may form the basis for a novel, low-cost energy storage system, according to a new study. The technology could facilitate the use of renewable energy sources such as solar, wind, and tidal power by allowing energy networks to remain stable despite fluctuations in renewable energy supply.
The two materials, the researchers found, can be combined with water to make a supercapacitor — an alternative to batteries — ...